Literature DB >> 14699953

Trafficking the NGF signal: implications for normal and degenerating neurons.

Jean-Dominique Delcroix1, Janice Valletta, Chenbiao Wu, Charles L Howe, Chun-Fai Lai, John D Cooper, Pavel V Belichenko, Ahmad Salehi, William C Mobley.   

Abstract

Nerve growth factor (NGF) activates TrkA to trigger signaling events that promote the survival, differentiation and maintenance of neurons. The mechanism(s) that controls the retrograde transport of the NGF signal from axon terminals to neuron cell bodies is not known. The 'signaling endosome' hypothesis stipulates that NGF, TrkA and signaling proteins are retrogradely transported on endocytic vesicles. Here, we provide evidence for the existence of signaling endosomes. Following NGF treatment, clathrin-coated vesicles (CCVs) contain NGF bound to TrkA together with activated signaling proteins of the Ras/pErk1/2 pathway. NGF signals from isolated CCVs through the Erk1/2 pathway. Early endosomes appear to represent a second type of signaling endosomes. We found that NGF induced a sustained activation of Rap1, a small monomeric GTP-binding protein of the Ras family, and that this activation occurred in early endosomes that contain key elements of Rap1/pErk1/2 pathway. We discuss the possibility that the failure of retrograde NGF signaling in a mouse model of Down syndrome (Ts65Dn) may be due to the failure to retrograde transport signaling endosomes. It is important to define further the significance of signaling endosomes in the biology of both normal and degenerating neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14699953     DOI: 10.1016/s0079-6123(03)46001-9

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  23 in total

1.  Nerve growth factor-mediated neurite outgrowth via regulation of Rab5.

Authors:  Jay Liu; Darija Lamb; Margaret M Chou; Yong-Jian Liu; Guangpu Li
Journal:  Mol Biol Cell       Date:  2007-01-31       Impact factor: 4.138

2.  Endocytosis and recycling of AMPA receptors lacking GluR2/3.

Authors:  Virginie Biou; Samarjit Bhattacharyya; Robert C Malenka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

Review 3.  Axonal transport defects in neurodegenerative diseases.

Authors:  Gerardo A Morfini; Matthew Burns; Lester I Binder; Nicholas M Kanaan; Nichole LaPointe; Daryl A Bosco; Robert H Brown; Hannah Brown; Ashutosh Tiwari; Lawrence Hayward; Julia Edgar; Klaus-Armin Nave; James Garberrn; Yuka Atagi; Yuyu Song; Gustavo Pigino; Scott T Brady
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

4.  Compartmental protein expression of Tau, GSK-3beta and TrkA in cholinergic neurons of aged rats.

Authors:  G Niewiadomska; M Baksalerska-Pazera; I Lenarcik; G Riedel
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 5.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

6.  (H)Elping nerve growth factor: Elp1 inhibits TrkA's phosphatase to maintain retrograde signaling.

Authors:  David R Kaplan; William C Mobley
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

7.  Enhanced β-secretase processing alters APP axonal transport and leads to axonal defects.

Authors:  Elizabeth M Rodrigues; April M Weissmiller; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2012-07-27       Impact factor: 6.150

8.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.

Authors:  Yasuo Ihara; Maho Morishima-Kawashima; Ralph Nixon
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

9.  Nitric oxide-NGF mediated PPTA/SP, ADNP, and VIP expression in the peripheral nervous system.

Authors:  Thimmasettappa Thippeswamy; Mark R Howard; Anna Siobhan Cosgrave; Daleep Kumar Arora; Jennifer S McKay; John P Quinn
Journal:  J Mol Neurosci       Date:  2007-09-11       Impact factor: 3.444

10.  Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.

Authors:  D Colas; B Chuluun; D Warrier; M Blank; D Z Wetmore; P Buckmaster; C C Garner; H C Heller
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.